Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 7:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 255 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Graft Failure Clear all
Completed Not applicable Interventional Results available

Robotic Harvest of the Latissimus Dorsi (LD) Muscles

NCT02274493
View directory record Official record
Conditions
Other Reconstructive Surgery, Failure of Muscle Graft, Cancer, Complications, Surgical Procedure, Unspecified
Interventions
da Vinci® Robotic Surgical System, LD muscle flap harvest procedure, Reconstructive surgery, Questionnaires
Device · Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 5, 2026, 7:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Berinert (C1INH) vs Placebo for DGF/IRI

NCT04696146
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Diseases
Interventions
Berinert, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 5, 2026, 7:15 PM EDT
Completed Not applicable Interventional

Evaluation of Safety and Effectiveness of The SherpaPak in Donation After Circulatory Death Heart Transplantation

NCT05038943
View directory record Official record
Conditions
Heart Transplant Failure, Determination of Death, Outcomes Research, Extracorporeal Membrane Oxygenation
Interventions
Paragonix SherpaPak Cardiac Transport System
Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 5, 2026, 7:15 PM EDT
Terminated Phase 2Phase 3 Interventional

The Boston Scientific ACCESS Trial

NCT00260728
View directory record Official record
Conditions
Renal Disease, Kidney Failure
Interventions
vascular access graft implantation
Device
Lead sponsor
Maquet Cardiovascular
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
8
States / cities
Long Beach, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2012 · Synced Sep 5, 2026, 7:15 PM EDT
Recruiting No phase listed Observational

Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs

NCT06532890
View directory record Official record
Conditions
Cardiac Failure, Graft Rejection
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
Up to 18 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Aurora, Colorado • Chicago, Illinois • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 5, 2026, 7:15 PM EDT
Withdrawn Phase 4 Interventional

Belatacept in Kidney Transplantation of Moderately Sensitized Patients

NCT02130817
View directory record Official record
Conditions
End Stage Renal Disease, Antibody Mediated Rejection
Interventions
Belatacept, Tacrolimus withdrawal, Plasmapheresis/Intravenous Immunoglobulin G, Thymoglobulin (ATG), Myfortic, Steroids
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 16, 2018 · Synced Sep 5, 2026, 7:15 PM EDT
Terminated Phase 2 Interventional Results available

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

NCT00720629
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Visilizumab, Tacrolimus, Methotrexate, Antithymocyte globulin (ATG)
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Sep 5, 2026, 7:15 PM EDT
Enrolling by invitation Not applicable Interventional

Xeltis Hemodialysis Access Graft (aXess) US Study

NCT06494631
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Xeltis Hemodialysis Access (aXess) graft
Device
Lead sponsor
Xeltis
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
7
States / cities
Phoenix, Arizona • Tuscon, Arizona • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 5, 2026, 7:15 PM EDT
Completed Phase 2 Interventional Results available

Reduced Intensity Conditioning Using CD3+/CD19+ Depletion for Non Malignant Transplantable Diseases

NCT02277639
View directory record Official record
Conditions
Bone Marrow Failure Syndromes, Immunodeficiencies, Immune Dysregulation Syndromes
Interventions
CliniMACs device
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 22 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Sep 5, 2026, 7:15 PM EDT
Enrolling by invitation Phase 2 Interventional

Chronic Exogenous Ketosis in HFpEF

NCT06937320
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Normal Ejection Fraction, Heart Failure, Diastolic
Interventions
Exogenous Ketone Drink, Placebo
Dietary Supplement
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 5, 2026, 7:15 PM EDT
Terminated Phase 3 Interventional

Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk

NCT00447187
View directory record Official record
Conditions
Corneal Diseases, Cornea Transplant
Interventions
LX201, Placebo
Drug · Other
Lead sponsor
Lux Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
24
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Sep 5, 2026, 7:15 PM EDT
Completed Phase 3 Interventional

Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures

NCT00042081
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
CGT003 (E2F Duplex Decoy)
Drug
Lead sponsor
Anesiva, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
154
States / cities
Birmingham, Alabama • Daly City, California • Los Angeles, California + 89 more
Source: ClinicalTrials.gov public record
Updated May 4, 2006 · Synced Sep 5, 2026, 7:15 PM EDT
Terminated Not applicable Interventional Results available

BRIDGE Device for Post-operative Pain Control

NCT03265249
View directory record Official record
Conditions
Liver Failure, Liver Diseases, Alcoholic, Liver Diseases, Pain, Postoperative, Transplant; Failure, Liver, Liver Cirrhosis, Biliary
Interventions
BRIDGE device
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 5, 2026, 7:15 PM EDT
Completed Phase 3 Interventional Results available

Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

NCT00755040
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
cyclosporine ophthalmic emulsion, placebo
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
5
States / cities
Palo Alto, California • Chicago, Illinois • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Sep 5, 2026, 7:15 PM EDT
Not yet recruiting Phase 2 Interventional

Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases

NCT07660783
View directory record Official record
Conditions
Bone Marrow Failure, Hemoglobinopathies, Primary Immune Deficiency (PID), Autoimmune Cytopenia, Immune Dysregulation, Hemophagocytic Lymphohistiocytosis (HLH), Non Malignant Disorders
Interventions
ALLOGENEIC CD34+ ENRICHED AND CD45RA- DEPLETED PBSCs
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
6 Months to 50 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 5, 2026, 7:15 PM EDT
Recruiting No phase listed Observational

Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver Transplant

NCT06950788
View directory record Official record
Conditions
Cirrhosis, Liver, Diabetes Mellitus Risk, Transplant; Failure, Liver, Transplant-Related Disorder
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 5, 2026, 7:15 PM EDT
Completed Phase 1 Interventional

Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure

NCT00062621
View directory record Official record
Conditions
Kidney Failure, Chronic, Multiple Myeloma
Interventions
Combined bone marrow and kidney transplant
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Sep 5, 2026, 7:15 PM EDT
Active, not recruiting Phase 2 Interventional

Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant

NCT03924401
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Abatacept
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 20 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Wilmington, Delaware • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 5, 2026, 7:15 PM EDT
Recruiting No phase listed Observational

PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis

NCT06422871
View directory record Official record
Conditions
End Stage Renal Disease, Hemodialysis Access Failure
Interventions
HeRO® Graft System or Super HeRO® System
Device
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Sarasota, Florida • Raleigh, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 5, 2026, 7:15 PM EDT
Not listed No phase listed Observational

Utilizing Technology for Optimization of Pain Management and Mobilization in High Risk Cardiac Surgical ICU Patients

NCT04146727
View directory record Official record
Conditions
Transplant; Failure, Heart, Heart Failure, Congestive, Lung Transplant Failure
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
168 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Sep 5, 2026, 7:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study of Cytokine and Inflammatory Markers in Patients With Chronic Renal Failure

NCT00565994
View directory record Official record
Conditions
Chronic Renal Failure
Interventions
Blood Draw
Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 27, 2010 · Synced Sep 5, 2026, 7:15 PM EDT
Completed No phase listed Observational

The Use of Aging Biomarkers to Predict Adverse Outcomes After Cardiac Surgery

NCT02496234
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Sapere Bio
Industry
Eligibility
50 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Sep 5, 2026, 7:15 PM EDT
Not listed No phase listed Observational

Analysis of Donor-derived Cell Free DNA in Liver Transplant Patients

NCT06225206
View directory record Official record
Conditions
Liver Transplant Failure
Interventions
donor-derived cell free DNA in liver
Behavioral
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Sep 5, 2026, 7:15 PM EDT
Terminated Phase 1Phase 2 Interventional

Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1H

NCT00048399
View directory record Official record
Conditions
Graft Failure
Interventions
Fludarabine, CAMPATH 1H, FK506, Stem Cell Transplantation
Drug · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 64 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 5, 2026, 7:15 PM EDT